NCT01301820View on ClinicalTrials.gov

Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)

PHASE2CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

azacitidine

azacitidine sc 75 mg/m²/d (d1- d7)

DRUG

Lenalidomide

lenalidomide 10mg/d (d1- d21)

Trial Locations (1)

49033

Mathilde HUNAULT BERGER, Angers

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

French Innovative Leukemia Organisation

OTHER